**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 57234

**Manuscript Type:** LETTER TO THE EDITOR

**Do available data support the widespread adoption of pancreatoscopy guided-lithotripsy?**

De Luca L. Pancreatoscopy guided-lithotripsy

Luca De Luca

**Luca De Luca,** Gastroenterology and Digestive Endoscopy Unit, Ospedali Riuniti Marche Nord, Pesaro 61121, Italy

**Author contributions:** De Luca L contributed alone to the study, he has read and agreed to the published version of the manuscript.

**Corresponding author: Luca De Luca, MD, Doctor,** Gastroenterology and Digestive Endoscopy Unit, Ospedali Riuniti Marche Nord, Piazzale Cinelli 1, Pesaro 61121, Italy. lucadeluca1210@gmail.com

**Received:** May 29, 2020

**Revised:** July 23, 2020

**Accepted:** August 25, 2020

**Published online:** September 16, 2020

**Abstract**

Peroral pancreatoscopy (POPS) is a demanding endoscopic procedure that can be used to perform intracanal lithotripsy in obstructing pancreatic stones but the experience is limited. Most stones can be removed successfully by endoscopic retrograde cholangio-pancreatography but patients with large stones require advanced therapeutic approaches, such as extracorporeal shock wave lithotripsy (alone or followed by endoscopic retrograde cholangio-pancreatography), currently the mainstay of treatment. Unfortunately, in about 10% of cases, extracorporeal shock wave lithotripsy can fail; moreover, it is not be available in many institutions. For this subgroup of patients, POPS guided-lithotripsy can play a role and have benefits. The most consistent study concerns a retrospective multicenter analysis that enrolled few patients per center. Considering the epidemiological scenario and the scant volume of skilled endoscopists, POPS must be developed in very few high-volume referral centers with standardized pathways and capable of performing multi-modality treatment. In addition, we could reasonably assume that POPS-guided-lithotripsy should be used as rescue therapy in special situations, identifying the ideal candidate who can achieve the maximum clinical result, and carefully balancing risk/benefits ratio.

**Key words:** Pancreatic stones; Pancreatoscopy guided-lithotripsy; Rescue therapy; Extracorporeal shock wave lithotripsy; endoscopic retrograde cholangio-pancreatography; Referral centers

**Citation**: De Luca L. Do available data support the widespread adoption of pancreatoscopy guided-lithotripsy? *World J Gastrointest Endosc* 2020; 12(9): 317-319

**URL**: https://www.wjgnet.com/1948-5190/full/v12/i9/317.htm

**DOI**: https://dx.doi.org/10.4253/wjge.v12.i9.317

**Core tip:** In chronic pancreatitis, the goal of treatment is reducing pain by eliminating obstructing pancreatic stones. There are several minimally invasive treatment approaches, such as extracorporeal shock wave lithotripsy and/or endoscopic retrograde cholangio-pancreatography; but where they fail, more advanced therapeutic techniques can be used. Peroral pancreatoscopy guided-lithotripsy is an appropriate option but should be performed as rescue therapy by experienced endoscopists in very few high-volume referral centers.

**TO THE EDITOR**

Peroral pancreatoscopy (POPS) is an endoscopic, challenging procedure to directly visualize the main pancreatic duct, permitting tissue acquisition, and can be also used for therapeutic purposes, such as intracanalar lithotripsy[1]. Although in the last decade technology has been continuing to improve with the recent development of single-operator digital cholangio-pancreatoscopy, pancreatic experience is limited.

In chronic pancreatitis, the goal of treatment is reducing pain by eliminating obstructing pancreatic stones. While the use of cholangioscopy for difficult biliary stones’ management is well documented, most pancreatic stones (< 5 mm) can be removed successfully by endoscopic retrograde cholangio-pancreatography (commonly known as ERCP). Patients with large stones require advanced therapeutic approaches, such as extracorporeal shock wave lithotripsy (ESWL) (alone or followed by ERCP), currently the mainstay of treatment. Unfortunately, in about 10% of cases, ESWL can fail or not be suitable; moreover, it is not available in many institutions. In this subgroup of patients, POPS guided-lithotripsy (POPS-gl) can play a role and have benefits.

“Extrema ratio” surgery offers the best long-term results for chronic pancreatitis. being associated with a lower rate of relapse[2]; although, the biggest criticism of any study is that neither ESWL nor POPS-gl was included in the endoscopic arm. We must keep in mind that not all endoscopists performing cholangioscopy routinely have dexterity in direct intraluminal lithotripsy for difficult biliary stones’ treatment. This further restricts the field of endoscopist experts. Nowadays, if you look at the available literature, you realize the low volume of patients treated and that data must be interpreted with caution.

The most consistent study concerns a retrospective analysis involving 17 centers in the United States and Europe, where just over 100 cases (about 6 patients per center!) treated with POPS-gl were enrolled during 3 years[3]. In others published reports, describing a systematic review[4] and a retrospective multicenter cohort[5], the authors collected a total of 87 and 28 patients, respectively. From all these data, the scant volume of skilled endoscopists and the epidemiological scenario, we believe POPS must be developed in very few high-volume referral centers with standardized pathways and capable of performing multi-modality treatment.

In addition, we could reasonably assume that POPS-gl should be used as rescue therapy in special situations and will be associated fewer interventions, more wide de-obstructions and lower risk of infection. Thus, it seems wise to implement a new level of evidence in order to identify the ideal candidate who can achieve the maximum clinical result, while carefully balancing risk/benefits ratio.

**REFERENCES**

1 **De Luca L**, Repici A, Koçollari A, Auriemma F, Bianchetti M, Mangiavillano B. Pancreatoscopy: An update. *World J Gastrointest Endosc* 2019; **11**: 22-30 [PMID: 30705729 DOI: 10.4253/wjge.v11.i1.22]

2 **Cahen DL**, Gouma DJ, Laramée P, Nio Y, Rauws EA, Boermeester MA, Busch OR, Fockens P, Kuipers EJ, Pereira SP, Wonderling D, Dijkgraaf MG, Bruno MJ. Long-term outcomes of endoscopic *vs* surgical drainage of the pancreatic duct in patients with chronic pancreatitis. *Gastroenterology* 2011; **141**: 1690-1695 [PMID: 21843494 DOI: 10.1053/j.gastro.2011.07.049]

3 **Brewer Gutierrez OI**, Raijman I, Shah RJ, Elmunzer BJ, Webster GJM, Pleskow D, Sherman S, Sturgess RP, Sejpal DV, Ko C, Maurano A, Adler DG, Mullady DK, Strand DS, DiMaio CJ, Piraka C, Sharahia R, Dbouk MH, Han S, Spiceland CM, Bekkali NLH, Gabr M, Bick B, Dwyer LK, Han D, Buxbaum J, Zulli C, Cosgrove N, Wang AY, Carr-Locke D, Kerdsirichairat T, Aridi HD, Moran R, Shah S, Yang J, Sanaei O, Parsa N, Kumbhari V, Singh VK, Khashab MA. Safety and efficacy of digital single-operator pancreatoscopy for obstructing pancreatic ductal stones. *Endosc Int Open* 2019; **7**: E896-E903 [PMID: 31281875 DOI: 10.1055/a-0889-7743]

4 **Beyna T**, Neuhaus H, Gerges C. Endoscopic treatment of pancreatic duct stones under direct vision: Revolution or resignation? Systematic review. *Dig Endosc* 2018; **30**: 29-37 [PMID: 28656688 DOI: 10.1111/den.12909]

5 **Attwell AR**, Patel S, Kahaleh M, Raijman IL, Yen R, Shah RJ. ERCP with per-oral pancreatoscopy-guided laser lithotripsy for calcific chronic pancreatitis: a multicenter U.S. experience. *Gastrointest Endosc* 2015; **82**: 311-318 [PMID: 25841585 DOI: 10.1016/j.gie.2015.01.020]

**Footnotes**

**Conflict-of-interest statement:** No conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/Licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 29, 2020

**First decision:** July 21, 2020

**Article in press:** August 25, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Sah DN, Xu ZL **S-Editor:** Ma YJ **L-Editor:** Filipodia **P-Editor:** Wang LL